SCHEMBL2332607

SCHEMBL2332607

CC(C)(C)OC(=O)N1CCC(Nc2nc(-c3ccccc3O)nc3ccc(Br)cc23)C1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 5/20 0.54
PIK3CD O00329 2/20 0.48
BTK Q06187 1/20 0.47
USP30 Q70CQ3 3/20 0.47
SMARCA2 P51531 2/20 0.47
SMARCA4 P51532 2/20 0.47
PBRM1 Q86U86 2/20 0.47
MEN1 O00255 1/20 0.46
HSP90AA1 P07900 1/20 0.46
KMT2A Q03164 1/20 0.46
PIM1 P11309 2/20 0.44
PIM2 Q9P1W9 2/20 0.44
NSD2 O96028 1/20 0.44
CHEK1 O14757 2/20 0.44
DNMT3A Q9Y6K1 1/20 0.43
PIK3CA P42336 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2332611 1.00 CHEK2 (0.54) CHEK2PIK3CDBTKUSP30SMARCA2
SCHEMBL2335247 0.94 CHEK2 (0.54) CHEK2PIK3CDBTKUSP30SMARCA2
SCHEMBL2335252 0.94 CHEK2 (0.54) CHEK2PIK3CDBTKUSP30SMARCA2
SCHEMBL9966984 0.91 CHEK2 (0.54) CHEK2PIK3CDBTKUSP30MEN1
SCHEMBL2330212 0.90 DNMT3A (0.49) CHEK2PIK3CDBTKUSP30NSD2
SCHEMBL9966892 0.90 CHEK2 (0.52) CHEK2PIK3CDBTKUSP30SMARCA2
SCHEMBL2330209 0.90 DNMT3A (0.49) CHEK2PIK3CDBTKUSP30NSD2
SCHEMBL2328353 0.88 CHEK2 (0.59) CHEK2PIK3CDMEN1HSP90AA1KMT2A
SCHEMBL2328109 0.86 CHEK2 (0.49) CHEK2PIK3CDBTKUSP30SMARCA2
SCHEMBL2328113 0.86 CHEK2 (0.49) CHEK2PIK3CDBTKUSP30SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324226-B2 Therapeutic oxy-phenyl-aryl compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-12-04 US disclosed
EP-2227460-B1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2012-06-20 EP disclosed
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-08-18 US disclosed
EP-2227460-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-09-15 EP disclosed
WO-2009053694-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CHEK2, CHEK1, PLK1 CHEK2 1/4885PIK3CD 515/4885BTK 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.